Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.36 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.36 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 4/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1227845 | 0.93 | MAPK1 (0.45) | MAPK1PTGS2ALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL1227972 | 0.88 | MAPK1 (0.41) | MAPK1PTGS2ALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL1226413 | 0.87 | ALDH1A1 (0.43) | MAPK1PTGS2ALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL1227748 | 0.84 | TSHR (0.40) | MAPK1PTGS2ALDH1A1SMN1; SMN2TSHR | |
| SCHEMBL1227801 | 0.82 | TSHR (0.44) | MAPK1PTGS2ALDH1A1SMN1; SMN2KCNQ2 | |
| SCHEMBL1226526 | 0.81 | PTGS2 (0.38) | MAPK1PTGS2ALDH1A1MCHR1TSHR | |
| SCHEMBL1227916 | 0.81 | TSHR (0.41) | ALDH1A1SMN1; SMN2TSHRLMNAMAPT | |
| SCHEMBL1227596 | 0.81 | TSHR (0.41) | ALDH1A1SMN1; SMN2TSHRLMNAMAPT | |
| SCHEMBL1227725 | 0.81 | LMNA (0.47) | ALDH1A1SMN1; SMN2KCNQ2TSHRLMNA | |
| SCHEMBL1228037 | 0.81 | NPSR1 (0.43) | MAPK1PTGS2ALDH1A1SMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150051195-A1 | NOVEL VIRAL REPLICATION INHIBITORS | CISTIM LEUVEN VZW (BE) | 2015-02-19 | — | — | US | disclosed |
| US-8906906-B2 | Viral replication inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2014-12-09 | — | — | US | disclosed |
| EP-2462122-A1 | NOVEL VIRAL REPLICATION INHIBITORS | Katholieke Universiteit Leuven (BE) | 2012-06-13 | — | — | EP | disclosed |
| US-20120129840-A1 | NOVEL VIRAL REPLICATION INHIBITORS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2012-05-24 | — | — | US | disclosed |
| WO-2011015641-A1 | NOVEL VIRAL REPLICATION INHIBITORS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2011-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129840-A1 | NOVEL VIRAL REPLICATION INHIBITORS | MAVS, EIF2AK2, SAMHD1 | MAPK1 2348/4885PTGS2 1901/4885ALDH1A1 3260/4885 |
| US-20150051195-A1 | NOVEL VIRAL REPLICATION INHIBITORS | MAVS, EIF2AK2, SAMHD1 | MAPK1 2348/4885PTGS2 1901/4885ALDH1A1 3260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.